Remote Monitoring of Patients With an Inflammatory Bowel Disease Under no

Status Not yet recruiting

Clinical Trial Summary

Routine follow-up of patients with inflammatory bowel disease (IBD) under stable doses of maintenance therapy or no IBD-related therapy at all, consists of intensive monitoring with prescheduled outpatient visits every six or twelve months. However, many of these patients do not require additional interventions from the IBD specialist during these visits. In addition, patients in long-term remission, often request a less frequent follow-up in the hospital and in consequence a less frequent absence from school or work. In conclusion, these routinely follow-up visits might put unnecessary burden on both healthcare providers and IBD patients, as well as on healthcare resources. Until now, no clear standard was set for how to organize a remote monitoring programme that is feasible and safe in a large patient population. Despite the possible added value of remote monitoring for IBD patients on stable or no therapy and who are in remission, they are seldomly the targeted population in clinical trials analysing the effects of remote monitoring in IBD. Secondly, a significant reduction in outpatient clinic visits, is often not actively included in the programme, but more an outcome result. Finally, to compose a safe remote monitoring programme, subjective and objective parameters of disease activity should be collected. With the ROADMAP study, the main objective is to evaluate the safety and feasibility of remote monitoring in IBD patients that are stable on their current therapy or receive no IBD-related therapy. Secondly, a health economic evaluation will be conducted. Patients will be randomised to either the remote monitoring group or control group. The remote monitoring group will visit the outpatient clinic after two years. During this two-year period, patients will be monitored remotely via three-monthly questionnaires (PRO-2, IBD disk, WPAI, EQ-5D-5L) and faecal calprotectin measures. An IBD nurse will evaluate all incoming data and act in case of red flags.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06338930
Study type	Interventional
Source	Universitaire Ziekenhuizen KU Leuven
Contact	Marc Ferrante
Phone	016 342845
Email	marc.ferrante@uzleuven.be
Status	Not yet recruiting
Phase	N/A
Start date	July 1, 2024
Completion date	March 30, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04046913` - The ADDapt Diet in Reducing Crohn's Disease Inflammation	N/A
Recruiting	`NCT05169593` - Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy	Phase 4
Recruiting	`NCT06116604` - Early Bowel Resection for Terminal Ileal Crohn's Disease
Recruiting	`NCT05627128` - A Culturally Tailored Dietary Intervention to Treat Crohn's Disease	N/A
Recruiting	`NCT05316584` - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy	N/A
Recruiting	`NCT05294107` - Intestinal Organoids	N/A
Withdrawn	`NCT04349449` - ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
Completed	`NCT05051943` - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed	`NCT03058679` - Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease	N/A
Completed	`NCT02871635` - BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity	Phase 3
Recruiting	`NCT04539665` - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease.	N/A
Recruiting	`NCT04266600` - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease	N/A
Recruiting	`NCT03913572` - Treatment of Perianal Disease Using Adipose-derived Stem Cells
Completed	`NCT03668249` - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Completed	`NCT03606499` - Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
Terminated	`NCT04102111` - A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease	Phase 2
Recruiting	`NCT04997733` - Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal	Phase 3
Recruiting	`NCT05906576` - Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients	Phase 4
Not yet recruiting	`NCT04398836` - Preoperative Nutrition for Crohn's Disease Patients	Phase 3
Not yet recruiting	`NCT04502303` - 18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Remote Monitoring of Patients With an Inflammatory Bowel Disease Under no or Maintenance Therapy — ROADMAP

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms